血液透析患者SARS-CoV-2疫苗接种的临床疗效
智利全国多中心观察性队列评估2021年2月至8月慢性血液透析终末期肾病患者接种SARS-CoV-2疫苗的临床疗效。共纳入12301例患者,完全接种预防感染效力18.1%(95%CI 11.8-23.8%),预防死亡效力66.0%(95%CI 60.6-70.7%)。BNT162b2与CoronaVac均有效,BNT162b2预防感染和死亡效力更高。
要点
- 完全接种预防感染效力18.1%,预防死亡效力66.0%。
- BNT162b2预防感染42.6%、死亡90.4%,CoronaVac分别为15.0%、64.8%。
- 全程随访中1362例(11.0%)发生COVID-19,150例死亡,病死率11.0%。
核心结论
- 研究结果表明,慢性血液透析患者接种SARS-CoV-2疫苗在预防感染和COVID-19相关死亡方面有效。
研究设计与样本
- 智利全国多中心观察性队列,评估2021年2月至2021年8月慢性血液透析终末期肾病患者的抗SARS-CoV-2疫苗临床疗效。
- 评估了BNT162b2(辉瑞-BioNTech)和CoronaVac(科兴)疫苗。
- 共评估12301例患者,其中10615例(86.3%)完成全程接种(2剂),490例(4.0%)接种不完整,1196例(9.7%)未接种。
主要发现
- 随访期间1362例(11.0%)患者发生COVID-19,150例死亡,病死率11.0%。
- 全程接种预防感染的效力为18.1%(95%CI 11.8-23.8%),预防死亡的效力为66.0%(95%CI 60.6-70.7%)。
- BNT162b2和CoronaVac均能有效减少感染和COVID-19相关死亡。
- BNT162b2预防感染效力为42.6%,CoronaVac为15.0%。
- BNT162b2预防死亡效力为90.4%,CoronaVac为64.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The COVID-19 pandemic is a global public health problem. Patients with end-stage renal disease on hemodialysis are at a higher risk of infection and mortality than the general population. Worldwide, a vaccination campaign has been developed that has been shown to reduce severe infections and deaths in the general population. However, there are currently limited data on the clinical efficacy of vaccinations in the hemodialysis population. METHODS: A national multicenter observational cohort was performed in Chile to evaluate the clinical efficacy of anti-SARS-CoV-2 vaccination in end-stage renal disease patients on chronic hemodialysis from February 2021 to August 2021. In addition, the BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines were evaluated. The efficacy of vaccination in preventing SARS-CoV-2 infection, hospitalizations, and deaths associated with COVID-19 was determined. RESULTS: A total of 12,301 patients were evaluated; 10,615 (86.3%) received a complete vaccination (2 doses), 490 (4.0%) received incomplete vaccination, and 1196 (9.7%) were not vaccinated. During follow-up, 1362 (11.0%) patients developed COVID-19, and 150 died (case fatality rate: 11.0%). The efficacy of the complete vaccination in preventing infection was 18.1% (95% confidence interval [CI]:11.8-23.8%), and prevention of death was 66.0% (95% CI:60.6-70.7%). When comparing both vaccines, BNT162b2 and CoronaVac were effective in reducing infection and deaths associated with COVID-19. Nevertheless, the BNT162b2 vaccine had higher efficacy in preventing infection (42.6% vs. 15.0%) and deaths (90.4% vs. 64.8%) compared to CoronaVac. CONCLUSION: The results of our study suggest that vaccination against SARS-CoV-2 in patients on chronic hemodialysis was effective in preventing infection and death associated with COVID-19.
引用
- Torres R, Toro L, Sanhueza ME, et al. Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients. Kidney Int Rep. 2022. PMID: 35874643. doi:10.1016/j.ekir.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。